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Major programs in psychiatric genetics have identiﬁed 4150 risk loci for psychiatric disorders. These loci converge on a small
number of functional pathways, which span conventional diagnostic criteria, suggesting a partly common biology underlying
schizophrenia, autism and other psychiatric disorders. Nevertheless, the cellular phenotypes that capture the fundamental features
of psychiatric disorders have not yet been determined. Recent advances in genetics and stem cell biology offer new prospects for
cell-based modeling of psychiatric disorders. The advent of cell reprogramming and induced pluripotent stem cells (iPSC) provides
an opportunity to translate genetic ﬁndings into patient-speciﬁc in vitromodels. iPSC technology is less than a decade old but holds
great promise for bridging the gaps between patients, genetics and biology. Despite many obvious advantages, iPSC studies still
present multiple challenges. In this expert review, we critically review the challenges for modeling of psychiatric disorders, potential
solutions and how iPSC technology can be used to develop an analytical framework for the evaluation and therapeutic
manipulation of fundamental disease processes.
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A NEED FOR DISEASE MODELS
Psychiatric disorders are associated with major economic, societal
and personal burdens. As a group, they constitute 13% of the global
burden of disease, and are the leading cause of disability
worldwide.1,2 Multiple lines of investigation from brain imaging,
studies of post-mortem brain tissue and genetic studies implicate
aberrant cellular function in the most serious psychiatric disorders
(for example, schizophrenia (SCZ), bipolar disorder, autism spectrum
disorder (ASD), anorexia nervosa and major depressive disorder).
However, these implications have not been tested in vitro, and this
relative lack of understanding of disease mechanisms hampers the
development of treatment. Induced pluripotent stem cells (iPSC)
technology is an exciting and very promising tool to generate new
disease models, with the ultimate goal of creating a new generation
of pathophysiology-relevant assays for in vitro drug screening.3
iPSC-based investigation has added advantages of permitting
temporal analyses of neurodevelopmental deﬁcits that are not as
readily available in animal studies and human studies, allowing
longitudinal cell studies that follow the progress of disease
processes from initiation to their end point.4–8 However, to develop
iPSC-based assays that truly reﬂect the pathophysiology of
psychiatric disorders, we need a precise understanding of which
molecular pathways and cellular structures are involved.
Here we review the search for cellular models and phenotypes
in the context of the current state of the art for SCZ genetics and
understanding gained from SCZ-related animal models (Figure 1).
We will discuss current capabilities and further developments
needed, potential pitfalls for stem cells reprogramming, culturing
and in vitro differentiation; and the establishment of relevant
cellular phenotypes that can be translated into disease models
(Figure 1), and ultimately into pharmaceutical targets for
psychiatric disorders.
ADVANCES IN PSYCHIATRIC GENOMICS: THE CASE OF SCZ
Decades of twin/family studies have compellingly established that
psychiatric disorders are heritable.9 However, the identiﬁcation of
causal genetic variants has, until recently, been notably difﬁcult.
Unprecedented advances in the past decade have shown that
psychiatric disorders are complex and inﬂuenced by the
combination of hundreds of common genetic variants each of
relatively small impact on disease risk and occassionally by rare
variants with larger effects.10 The ﬁeld has made major advances
in identiﬁcation of these risk variants, although it is clear that there
are more to be found, and how they combine together to create a
polygenic risk is currently unknown.
Genetic epidemiology provides strong support for a genetic
component for SCZ (with a heritability of ~ 0.64 in Nordic popu-
lation samples and 0.81 in a twin study meta-analysis).9–13
Common variation assessed by genome-wide association studies
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(GWAS) yields single nucleotide polymorphism-based heritability
estimates for SCZ over 0.30, and have yielded 108 independent
genomic risk loci.14,15 Critically, most loci identiﬁed in GWAS are
broad (median 129 kb) with small impact on SCZ risk (median
relative risk 1.08).14 Whole-exome sequencing studies for SCZ
identiﬁed no speciﬁc genes but implied a role for functional gene
sets, for example, voltage-gated calcium channels, ARC-associated
scaffold and FMRP interactors.
Copy number variation (CNV) studies for SCZ have yielded a
dozen CNVs that are robustly associated with SCZ, but also with
other psychiatric disorders.10,16,17 Findings from recent studies
suggest that a high polygenic burden adds to the SCZ risk in
carriers of CNVs, suggesting cumulative effects between common
and rare risk variants.14,18,19,20
SCZ, but also ASD, converge on common pathways; such as
within synaptogenesis and synapse function21,22 and epigenetic
processes,22,23 with many genes being highly expressed during
fetal cortical development.24–26
Despite these unprecedented advances in the genetics of SCZ,
very few of the current ﬁndings unequivocally implicate speciﬁc
individual genes that are easily ‘actionable’ for biological, clinical
or therapeutic studies. To be of value, such studies need to show
strong linkage between the genetic variation and a discriminative
phenotype that is relevant for the disorder. This connection is
both crucial for understanding the molecular pathways that lead
to SCZ and essential to develop iPSC-based assays that reﬂect SCZ
pathophysiology. A single variant of small effect is unlikely to yield
a measurable cellular phenotype, we therefore aim to model
either the cumulative effect of hundreds of risk variants of small
effect or a single variant of high penetrance or large effect.
iPSC technology27,28 has provided a highly promising tool to
investigate human disorders, and is especially well-suited to deal
with disorders that are not caused by a single mutation, such as
mental disorders.4,29 As iPSC studies rely on cells from patients,
one can select patients with a high genetic propensity for the
disease, either due to the accumulation of many common variants
of small effect or due to carrier status of a rare variant of large
effect. In addition, by utilizing cells from patients with a targeted
set of risk alleles, one also captures the complete genetic
background of an individual, which includes possible genetic
modiﬁers that are currently unidentiﬁed.4 Several initial iPSC
studies for SCZ have already been carried out and have yielded
proof-of-principle by successfully identifying differences in synap-
tic functions in iPSC-derived cells from patients. However, these
initial studies also clearly illustrate some of the pitfalls of iPSC
studies for identifying cellular traits associated with SCZ. We will
discuss these pitfalls in more detail below, after ﬁrst examining the
alternative approach of using animal models for SCZ and ASD.
RODENT MODELS IN THE STUDY OF SCZ AND AUTISM
Several approaches have been employed to produce rodent
models for SCZ and ASD. Rodents provide a number of general
advantages with respect to animal husbandry and handling, well-
established behavioral and physiological tests, and the availability
of transgenic manipulation.30,31 For example, maternal stress and
malnutrition, infection and hypoxic insult at birth have all been
implicated as developmental triggers of SCZ, and these can be
replicated in rodent models through manipulations such as
prenatal drug administration, disruption of neurogenesis during
gestational periods, neonatal ventral hippocampal lesions, post-
weaning social isolation and perinatal or maternal immune
activation (reviewed in ref. 30). Genetic manipulation has also
been employed to target several genes implicated in SCZ or ASD
in transgenic mice.31–42 An important caveat with respect to
transgenic models is that these are relatively easy to generate, and
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Figure 1. Brain correlates of in vitro iPSC cell phenotypes. Current analysis of patient iPSC offers a range of potential methods of cell
phenotyping that correlates to potential changes in brain pathology associated with psychiatric disorders. Gene expression (transcriptomic)
and protein expression (proteomic) proﬁling of in vitro neurodevelopment or iPSC-derived mature neuronal and glial cultures correlates with
brain development and processes associated with adult neurogenesis, such as some aspects of memory and learning. Cell analysis of
neurodevelopment, cell migration, cytoskeletal dynamic and synaptogenesis informs on the basic processes by which neurogenesis builds
and remodels the brain. Functional activity is measured by electrophysiological recording (for example, patch-clamp) and calcium or voltage
sensors (dyes and genetically encoded markers). Multicellular interactions (connectomics) can be investigated as structural interactions in
two-dimensional (2D), 3D and organoid cell co-culture, and at the functional level using multi-electrode and microelectrode array (MEA)
recordings. iPSC, induced pluripotent stem cell.
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thus may fuel research efforts that are actually red herrings
because the genes in question are not convincingly implicated in
the human diseases.43
Although rodents provide tractable and accessible platforms,
these are not without signiﬁcant shortcomings. First, although
each of the rodent models that are already established replicates
certain neurophysiological, neuroanatomical and/or behavioral
features of genetic mutations implicated in SCZ or ASD, none of
them fully recapitulates the complexity of these disorders. Thus,
the knowledge contributed by animal models to the etiology of
SCZ and ASD is by its nature fragmentary, with each model
providing a speciﬁc facet that needs to be integrated into a
greater whole that reﬂects the heterogeneity implicit in the
disorder itself. Second, animal models cannot be interrogated with
the necessary depth. Indeed, how can one gauge effects on
thought processes, perception and abstract learning in animals,
and when these can only be conveyed fully through language?
As a consequence, many core features of psychiatric disorders can
only be assessed indirectly or obliquely in animal models, with an
artiﬁcial focus on simpler behavioral and physiological features
that can be easily identiﬁed. The extent to which these can be
translated to the more complex symptomatology of the human
conditions is not always clear. Third, induction of disease states in
rodents may involve acute pharmacological or other insults that
do not accurately replicate the causes of psychiatric disorders in
humans. Even transgenic approaches targeting the same genes
may be inaccurate, since a manipulation as coarse as a single gene
knockout is unlikely to capture the complexity of the genetic
causes of psychiatric disorders. Moreover, the genomic landscapes
of the genes in question may differ in rodents and humans, and
genetic differences will also be compounded where genes and
environment interact extensively in disease development. Fourth,
rodents and humans have vastly different lifespans, which may
not be appropriately congruent with respect to the timeline of
disease development. Last, the pharmacology of potential drug
treatments may differ in the two species, creating false positives
and negatives in preclinical studies.
In conclusion, only a small percentage of psychiatric disorders is
caused by single gene variations and can be modeled with
transgenic mice. Indeed, many clinical studies based on promising
drug targets found in animals failed human translation. As a
consequence, the difﬁculties in modeling polygenic risk gene
variants and the human genetic background have made animal
models less attractive in modeling complex neurological
disorders. Nevertheless, transgenic mouse models advanced our
understanding of potential mechanisms regulated by genes
involved in psychiatric disorders. Table 1 compares some of the
principal advantages of transgenic mouse models and human
iPSC-based models.
CELL PHENOTYPING OF PATIENT IPSC
The key challenge for iPSC-based disease modeling is to identify
one or more relevant cellular phenotypes that accurately
represent the disease pathophysiology. Increasing numbers of
reports have demonstrated that for many diseases speciﬁc
pathophysiology can be captured in human iPSC-based disease
models. These range from cardiovascular disease,44,45 cancer,46,47
ocular disease,48,49 diabetes mellitus50,51 and neurological dis-
orders of the brain.52,53 Can the same approach be applied to
complex psychiatric disorders?
The problem is that almost all psychiatric disorders are
characterized by clinical signs and symptoms, but lack indepen-
dent veriﬁcation from objective biomarkers. Thus, how might
these clinical phenotypes manifest themselves in terms of cell
behavior? The identity of robust cellular ‘readouts’, which typify
any psychiatric disorder, is a crucial unsolved problem and an area
of intense study54 (Table 2). When satisfactorily answered, this will
herald a new degree of biological objectivity and quantiﬁcation
for the study of psychiatric disorders.
The aim is to ﬁnd a single or small number of cell phenotypes or
parameters that strongly associate with psychiatric disorders, and
establish a cellular proﬁle characteristic of cells derived from the
general patient population. Although a consensus set of cellular
phenotypes for psychiatric disorder is yet to be established, we
can deﬁne some of their desired characteristics. First, cellular
phenotypes have to relate to the biological pathways identiﬁed by
genetics. Second, although there are many risk genes in disparate
biological pathways, at some level, phenotypes should converge
onto a much smaller grouping. Third, phenotypes need to be
quantiﬁable. Finally, to be useful for drug development cellular
phenotypes should be reversed by pharmacological treatment,
although not necessarily by drugs in current use.
Although human iPSC-based approaches underrepresent the
complexity of the human central nervous system, cellular pheno-
types are likely to lie more proximal to molecular disease
mechanisms than phenotypes seen at the level of a tissue or
organism,55 and thus may bypass compensatory homeostatic
Table 1. Comparing advantages of transgenic mouse and human cell-based models
Experimental feature Advantage
Transgenic mouse Human iPSCs in vitro
Assessment of monogenic effects High High
Assessment of polygenic effects congruent with human disease Low High
Recapitulates genetic complexity of human disease Nil High
Recapitulates physiological complexity of human disease Moderate Low
Replication of age-dependence of human disease Low Low
Behavioral assessment High Nil
Cognitive assessment Low Nil
Neuroanatomical assessment High Nil
Neurophysiological assessment at cellular/subcellular level High High
Neurophysiological assessment at network level Moderate High
Neurophysiological assessment of neural networks with high throughput Low High
Neurophysiological assessment at systems level High Nil
Biochemical/epigenetic assessment at cellular/subcellular level Moderate High
Pharmacological assessment/drug testing relevant to human disease Moderate High
Abbreviation: iPSC, induced pluripotent stem cell.
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Table 2. Current in vitro and iPS models
Cell type (iPSCs, ESCs) Number of lines Phenotype Reference
Schizophrenia
Schizophrenia iPSC (genotype unknown) Healthy controls (6) Patients (4) (1) SCZ human iPSC neurons showed diminished neuronal connectivity in
conjunction with decreased neurite number, PSD95-protein levels and glutamate
receptor expression.
(2) Gene expression proﬁles of SCZ human iPSC neurons identiﬁed altered
expression of many components of the cyclic AMP and WNT signaling pathways.
(3) Key cellular and molecular elements of the SCZ phenotype were ameliorated
following treatment of SCZ iPSC neurons with the antipsychotic loxapine.
(4) Discovery-based approaches-microarray gene expression and stable isotope
labeling by amino acids in cell culture (SILAC) quantitative proteomic mass
spectrometry analyses: abnormal gene expression and protein levels related to
cytoskeletal remodeling and oxidative stress, and subsequently aberrant migration
and increased oxidative stress in SCZ iPSC NPCs observed.
(5) SCZ cases showed elevated levels of secreted DA, NE and Epi. Consistent with
increased catecholamines, the SZ neuronal cultures showed a higher percentage
of tyrosine hydroxylase (TH)-positive neurons, the ﬁrst enzymatic step for
catecholamine biosynthesis.
(6) Impaired differentiation into hippocampal granule cells.
(7) Decreased amplitude and frequency of sEPCs in hippocampal granule cells.
(8) Increased cell-to-cell variation in the HSF1 activation level among neural
progenitor cells (NPCs) differentiated from iPSCs derived from schizophrenia
patients.
56,66,124–
126
Schizophrenia iPSC: 15q11.2 microdeletion
haploinsufﬁciency of CYFIP1 that encodes a
subunit of the WAVE complex that regulates
cytoskeletal dynamics.
Healthy controls (3) Patients (3) (1) Deﬁcits in adherens junctions and apical polarity.
(2) Targeted human genetic association analyses revealed an epistatic interaction
between CYFIP1 and WAVE signaling mediator ACTR2 and risk for schizophrenia.
127
Schizophrenia iPSC 22q11.2 microdeletion (del) Healthy controls (2)
Patients (3)
Healthy controls (6)
Patients (3)
(1) A signiﬁcant delay in the reduction of endogenous OCT4 and NANOG
expression during differentiation.
(2) A number of genes involved in synaptogenesis that have been implicated in
SCZ and ASD are also increased in these early-differentiating neurons, including
NRXN1, NLGN1, RELN, CNTNAP2 and CTNNA2.
(1) 45 differentially expressed miRNAs were detected (13 lower in SZ and 32
higher).
(2) A signiﬁcant increase in the expression of several miRNAs was found in the
22q11.2 del neurons that were previously found to be differentially expressed in
autopsy samples and peripheral blood in SZ and autism spectrum disorders (for
example, miR-34, miR-4449, miR-146b-3p and miR-23a-5p).
128,129
Schizophrenia iPSC (genotype unknown) Control (1): aged match male
Patient (1): female SCZ patient
(1) Extra-mitochondrial oxygen consumption is increased in SCZ NPCs compared
with control NPCs
(2) NPCs from a SCZ patient had higher ROS levels, which were reverted by
valproic acid.
(3) NPCs from SCZ patient have higher levels of potassium and zinc.
(4) Valproate normalized the elevated zinc and potassium levels.
130,131
Schizophrenia iPSC DISC1 mutations Controls (3): 2 from same pedigree and 1
unrelated control
Patients (2): with the frameshift DISC1
mutation in same pedigree. Isogenic iPS
cell lines (3): 1 TALENs-corrected DISC1
iPS cell line; 2 TALENs-introduced DISC1
mutation (4-bp deletion)
Control (1): healthy human iPSC line YZ1
Isogenic DISC1 mutations (2): 1 TALENs-
introduced exon 8 frameshift; 1 CRISPR/
Cas-introduced exon 2 frameshit
(1) Density of SV2+ synaptic boutons is decreased in the SCZ neurons.
(2) Frequency, but not amplitude, of spontaneous synaptic currents is decreased,
suggesting presynaptic release defects.
(3) TALEN genome-editing shows that the DISC1 mutation is necessary and
sufﬁcient for these changes.
(4) Schizophrenia neurons show widespread transcriptional disturbances.
(1) An increased level of canonical Wnt signaling in neural progenitor cells.
(2) Decreased expression of fate markers such as Foxg1 and Tbr2 in both mutants.
(3) Both gene expression changes are rescued by antagonizing Wnt signaling in a
critical developmental window.
(4) Subtly alters neuronal fate but not neuronal maturity.
58,132
Schizophrenia iPSC (genotype unknown) Healthy control (2)
Patient (3): clozapine-treated
schizophrenia patients
(1) 12-day-old SCZ NPCs show decreased expression of nestin and increased
expression of PAX6 compared with control NPCs, suggesting a delay in
differentiation.
(2) SCZ NPCs differentiate into dopaminergic neurons (DaNs) with a lower yield
than control NPCs.
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Table 2. (Continued )
Cell type (iPSCs, ESCs) Number of lines Phenotype Reference
(3) SCZ glutamatergic neurons (GluNs) express lower levels of TBR, PSD95 and
synapsin1 than control GluNs.
(4) The mitochondrial membrane potential has a lower magnitude in SCZ NPCs,
GluNs and DaNs compared with control equivalent neural cells.
(5) The distribution of mitochondria inside neurons is more variable in SCZ NPCs,
GluNs and DaNs compared with control.
Schizophrenia iPSC (genotype unknown) Controls (6)
Patients (4)
(1) Expression of genes in the Wnt signaling pathway is increased in SCZ NPCs.
(2) Activity of the Wnt-β–catenin signaling cascade, as measured by the TOPFLASH
assay, is increased in SCZ NPCs compared with control.
61
ASD
Timothy syndrome (TS) iPSC: mutations in the
L-type calcium channel, Cav1.2.
Healthy controls (2) Patients (2) (1) Showed the TS-associated transcriptional changes.
(2) Activity-dependent dendrite retraction
(3) Defects in calcium-channel function
(4) Altered activity-dependent gene-expression/dendritic retraction
(5) Abnormality of lower cortical layer and callosal projection differentiation
(6) Abnormal catecholaminergic differentiation
134,135,57
Rett syndrome: MECP2 null Healthy controls (1) Patients (1) (1) A reduction in soma size.
(2) Fewer synapses, reduced spine density, smaller soma size, altered calcium
signaling and electrophysiological defects
(3) Reduced synaptic density was restored by treatment of IGF1 or gentamycine.
(4) Defect in neuronal maturation.
(5) Smaller nucleus size
(6) Impaired AKT/mTOR activity
(7) Mitochondria deﬁcit
(8) Decreased transcription in neurons.
136–140
Atypical Rett syndrome iPSCs: mutations of the
cyclin-dependent kinase-like 5 (CDKL5) and
netrin-G1 (NTNG1) genes
from two female patients: Healthy
CDKL5 (2) Mutant CDKL5 (2)
(1) Exhibit aberrant dendritic spines
(2) Impairs synaptic activity
(3) A signiﬁcantly reduced number of synaptic contact
141
Phelan–McDermid syndrome iPSCs: deletion of
SHANK3
Control: normal iPSC (1) and ESC (1)
Patients (2)
(1) Impaired excitatory (both AMPA and NMDA-mediated) but not inhibitory
synaptic transmission mainly due to loss of function of SHANK3.
(2) Reintroduction of SHANK3 and IGF1 application restore excitatory synaptic
transmission
142
Fragile X syndrome iPSC Control: wild-type-FMR1(2) Patients (3) (1) DNA methylation and transcriptional silencing even in the pluripotent stage.
(2) Neurons showed reduced neurite numbers and neurite lengths
(3) Fewer and shorter processes
143–145
Fragile X-associated tremor/ataxia syndrome
(FXTAS) iPSC:(FMR1)
From 1 patient: Control: wild-type-FMR1
(1) Premutation FMR1 (1)
(1) Shorter neurite length
(2) Fewer PSD95-positive synaptic puncta
(3) Sustained calcium response after glutamate application
146
15q11-q13.1 duplication (Dup15q) syndrome,
(CNV), iPSC
Control (1) Patients (4) (1) Gene copy number does not consistently predict expression levels in cells with
interstitial duplications of 15q11-q13.1.
(2) mRNA-Seq experiments show that there is substantial overlap in the genes
differentially expressed between 15q11-q13.1 deletion and duplication neurons.
147
ASD (NRXN1 mutation) Control: normal iPSC (1) and human ESC
(1)
Mutants: NRXN1 knockdown in neural
stem cells (2)
(1) Reduced glial differentiation
(2) Altered gene expression related to cell adhesion and neuron differentiation
148
ASD (NRXN1 mutation) Control: human ESC (1)
Mutants: human ESC (2) Heterozygous
Conditional NRXN1 mutations
(1) Decrease the frequency of spontaneous mEPSCs in neurons without affecting
synapse density.
(2) Impaired evoked neurotransmitter release but not the readily releasable pool of
vesicles.
(3) Increased CASK protein levels in neurons.
149
Idiopathic ASD (deletions in Chromosomes 10
or 14)
Control: unaffected, ﬁrst-degree family
members (1–3)
Patients (4)
(1) Signiﬁcantly perturbed in transcriptional regulation of cell proliferation/cell
fate, neuronal differentiation/process outgrowth and synaptic transmission.
(2) A signiﬁcant decrease in cell-cycle length in ASD-derived iPSCs and derived
neuronal progenitors.
(3) Accelerated or increased neuronal differentiation and synaptic connections.
(4) An increase in the number of inhibitory synapses in ASD-derived neurons.
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processes that buffer the effects of deleterious genetic variants in
whole tissues and organs (Table 2). Identiﬁcation of cellular
phenotypes may therefore offer a more direct readout of the
pathophysiological process (Figure 1). This, of course, would need
to be validated against clinical data. We discuss below various
ways to phenotype iPSC-derived patients cells and to interrogate
the phenotypes to extract information about the disorder.
‘OMIC’ APPROACHES TO CELL PHENOTYPING
Post-genomic technologies offer a battery of approaches for
proﬁling cell difference at both population and single-cell level.
Advances in RNA sequencing technologies and transcriptomics
provide one of the easiest and highest throughput approaches to
cell phenotyping, and potentially could be compared with
transcription proﬁles from brain biopsies or post-mortem tissue.
Transcriptome studies of both SCZ and ASD patient-derived cells
have identiﬁed hundreds of gene expression differences.56–59 To
date, however, there is no deﬁnitive or consensus RNA-based
transcription proﬁle associated with SCZ or ASD-derived iPSC, a
situation that is mirrored by post-mortem brain tissue proﬁling.60
Trends point to expression changes of genes involved in synaptic
structure, adhesion and transmission, and speciﬁc cell signaling
pathways particularly those associated with glutamate, Wnt and
cAMP signaling.61 These studies also often reveal overlap with
risk genes identiﬁed by both GWAS and CNV studies, and may
point to convergence on biological pathways rather than on
individual genes.
Mapping and measuring DNA methylation may extend
this analysis to provide unique epigenetic signatures. For example,
the methyl-cytosine-binding protein MeCP2 is causative of Rett’s
syndrome and is associated with ASD.62 Histone protein modiﬁ-
cations can be proﬁled using ChIP-seq and a number of histone
methyl transferase enzymes are associated with neuropsychiatric
disorders. Either alone, or more likely when combined with
expression data, epigenetic proﬁling may identify developmental
and activity-dependent cellular phenotypes.63–65
Proteomic technologies have also been used to investigate
patient iPSC phenotypes, backing up the results of transcriptional
proﬁling. Use of SILAC (stable isotope labeling by amino acids in
cell culture) in mass spectrometry to quantitate changes in protein
levels of neural progenitor cells (NPC) has shown decreases in the
SCZ-associated NLGN3 protein, and increases in the actin
cytoskeletal regulators Coﬁlin and Proﬁlin, and proteins associated
with oxidative stress.66 Protein proﬁling can be extended further
to protein function by investigating protein interactomes and
phosphoproteomes. An analysis of the protein complexes in
neuron-like SH-SY5Y cells showed a convergence of proteins
encoded by ASD associated genes onto a small number of protein
complexes.67 Phosphoproteomic analysis of iPSC-derived from
Phelan–McDermid syndrome (PMDS) patients, in which the post-
synaptic density protein SHANK3 is lost, and of neurons from
Shank3 knockdown mice, has revealed elevated activity of protein
kinase CLK2 and demonstrated its potential as a therapeutic
target.68
NEURODEVELOPMENTAL DEFICITS
A major advantage of patient-derived iPSC studies is the
possibility to follow neurodevelopment in vitro. Transcriptional
analyses are beginning to show that differences in neurodevelop-
ment may arise prior to overt neuronal differentiation, leading
to altered timing or cell differentiation fates of NPC.66 This ﬁts
with the potential neurodevelopmental component of psy-
chiatric conditions and the proﬁle of genetic risk. Transcriptional
differences can readily be conﬁrmed using the extensive range of
antibodies to neurodevelopmental marker proteins. Interestingly,
a number of CNV cases, such as PMDS and Timothy Syndrome, inTa
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which there is a deﬁcit in the voltage-gated calcium channel,
CACNA1C 57 show gene expression changes at the NPC stage. This
may reﬂect a feedback onto neurodevelopmental signaling due to
electrophysiological activity or cell contact-dependent gene
expression69 in determining developmental timing and differen-
tiation. Such studies raise the possibility that transcriptional
proﬁling of developmentally regulated gene expression in
patient-derived iPSC may reveal quantitatively robust and
disease-relevant phenotypes.
In addition to neuronal deﬁcits, abnormalities of all three glial
cell types have been observed in SCZ patients.70 Post-mortem
studies indicate that oligodendrocyte numbers are reduced, and
that oligodendrocyte maturation and morphology is impaired in
SCZ patients,71,72 although neuroleptic treatment and aging might
have confounded these results. Results from large-scale expres-
sion analyses and GWAS for SCZ,73–75 implicate changes in genes
that regulate cell-cycle control and oligodendrocyte maturation,
suggesting impaired cell-cycle exit and re-entry.71 Altered astro-
cyte numbers are also found in the brains of SCZ patients after
autopsy with early studies reporting astrogliosis,76 while more
recent studies indicate astrocyte cell loss in selected (sub)cortical
and callosal regions.77 GWAS demonstrates genetic variants in
genes involved in astrocyte function, including signal transduc-
tion, tyrosine kinase signaling, G protein–coupled receptor
signaling, small GTPase-mediated signaling, cell adhesion and
gene transcription.73 These ﬁndings are supported by results
from expression studies that showed altered expression levels
of astrocyte-associated genes, including GFAP,78 glutamine
synthetase79 and S100B.80 The involvement of biological pathways
associated with inﬂammation and immunity in the development
of SCZ is receiving increased attention, and is supported by
patient genetic studies, with variants found in several cytokine
genes,81,82 as well as the major histocompatibility complex
region83 where structural variants of the complement component
4 (C4) gene lead to increased activity.84 Previous studies have
indicated microglial activation and altered microglia-related gene
expression in postmortem brain tissue (reviewed by ref. 70). As
severe infections and aberrant immune responses are risk factors
for SCZ, this may point to gene–environment interactions for SCZ
and the use of anti-inﬂammatory drugs in treatment strategies.85
ALTERED NEURONAL CELL BIOLOGY AND FUNCTION
Beyond transcriptomics and neurodevelopment, other cell para-
meters may also be effective measures of cellular phenotype.
Brennand et al.66 noted reduced migration in neural precursor
cells from four SCZ patients, using a variety of assay formats.66 The
molecular mechanism for this is not entirely clear but correlates
with increased expression of adhesion molecules. Its relevance
may be signiﬁcant, since interneurons migrate from speciﬁc
progenitor domains to populate cortical and other regions during
brain development. Changes in morphology due to alterations of
the cytoskeleton have also been observed, suggesting more than
just an adhesion effect.86 Cytoskeletal effects could manifest later
in development as changes in neuroarchitecture and particularly
in dendritic spine morphology and dynamics. If of sufﬁcient
magnitude, such structural sequelae could lead to macroscopic
changes in brain anatomy that may correlate with larger scale
changes detected by human brain imaging.87 Computed tomo-
graphy and magnetic resonance imaging analyses have revealed
structural changes in the brain of SCZ patients, such as enlarged
lateral and third ventricles, smaller cortical volumes, smaller gray
matter volumes and larger basal ganglia (reviewed by ref. 88).
Morphometric changes generally do not progress overtime and
therefore may match histological ﬁndings in postmortem tissue,
which include altered cortical and hippocampal pyramidal neuron
size, decreased interneuron numbers and reduced dendritic spine
densities.88,89
At the subcellular level, altered synaptogenesis, synaptic vesicle
release and mitochondrial function have all been observed in
patient-derived iPSCs.58,62 Recently, mitochondrial abnormalities
have been detected using RNA sequencing and mitochondrial
assays, and hyperexcitability has been demonstrated by using
both patch-clamp recording and Ca2+ imaging in immature
neurons from patients with bipolar disorder.90
The gold standard for electrophysiological assessment is patch
clamping recording, and mature differentiated neurons are
assessable with this technique. However, this approach requires
obtaining high-resistance seals between the electrode tip and the
neuron surface for full effect, limiting throughput, even in
automated systems. An alternative is to use optical recording of
electrical events to monitor cell activity. This is most commonly
done indirectly by imaging calcium ﬂuctuations, using calcium
sensitive ﬂuorescent dyes or genetically encoded calcium
indicators.91 The latter approach has the added advantage that
genetically encoded calcium indicators can be selectively expressed
in speciﬁc cell types. Calcium recording, however, can only capture
events that involve changes in intracellular calcium concentration,
meaning that hyperpolarization and inhibitory synaptic events go
largely unrecognized, and it has low-temporal resolution. Voltage-
sensitive indicators on the other hand provide direct information
about changes in membrane potential irrespective of the cause
and the sign, permitting the assessment of both excitatory and
inhibitory synaptic interactions and depolarizing and hyperpolariz-
ing neurotransmitter and drug effects.92,93
Currently, the range of phenotypes seen in cellular studies of
neuropsychiatric disorders is diverse and variable, and there is a
need for a more systematic investigation across a range of
phenotypes. For example, effects on single-cell electrophysiologi-
cal parameters appear variable with no clear pattern. What is clear,
however, is that there do not seem to be major deﬁcits in the
basic electrophysiological behavior of neurons. Where differences
are emerging is in synaptic function and connectivity, ﬁndings
that ﬁt the types of pathways implicated by genetic analysis. This
may point to the major problem with single-cell measurements,
as the biology of neuropsychiatric disorders is ultimately an
emergent property of cell connectivity and network activity.
CELL INTERACTIONS AND NEURAL NETWORKS
Two general approaches can be taken to assay neural networks
and cell connectivity; one focuses on structural interaction, the
other on functional connectivity, although ideally these could be
combined to provide both structural and functional assemblies.
Conventional two-dimensional (2D) monocultures are limited in
their ability to form dynamic anatomical connections and may not
follow the same neurodevelopmental pathway, as cells within the
brain are both constrained by, and receiving signals from the
extracellular matrix and neighboring cells. 3D culture methods are
being explored to better mimic tissue architecture, and to study
cellular properties and network interactions in health and disease.
Ideally, these iPSC-based 3D culture platforms would involve co-
cultures of appropriate neuronal and glial cell types in a
mechanically appropriate matrix with soluble and extracellular
matrix-derived signals to those extant in the developing brain.
They would also be compatible with optical imaging for morpho-
logical and electrophysiological analysis. Current approaches are
based on the use of biomaterials to support 3D network
organization and/or the use of neural stem cell aggregates to
reconstruct complex in vivo-like structures (organoids). The range
of biocompatible materials being tested for 3D culture systems
includes hydrogel-based materials, 3D electrospun polymers,
synthetic scaffolds, silica beads and microﬂuidic bioreactors. At
present, we lack a full understanding of how biomaterials affect
cell properties, and 3D cultures systems have so far not been
widely explored for iPSC-based disease modeling.94–96 Organoids
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and aggregate cultures give prospects to reconstruct in vivo-like
neural circuits and to achieve insights into the signal integrated on
multiple levels.97 Through self-organization of complex tissue
patterns, attempts have been made to replicate various brain
regions to generate models of ASD.98–100 Of particular note, 3D
human ‘cortical spheroids’ generate a laminated cerebral cortex-
like structure containing electrophysiologically mature neurons
that form functional synapses.98 However, it is difﬁcult to control
the size and internal laminar structure of the spheroids, and robust
and reproducible methods need to be developed for quantiﬁca-
tion of both structure and physiology.
Functional network studies have substantial potential as drug-
screening platforms. Ideally, they should measure such network
behavior as the degree of connectivity (spread of impulses
through the network) and the synchrony and oscillation frequency
of neuronal ﬁring.101 In principle, these could mirror at the cellular
level the types of brain activity measured by electroencephalo-
gram, but at much higher spatial resolution. Human iPSCs can be
developed into functional neuronal network on in vitro micro-
electrode arrays,102–104 where network behavior has been shown
to be sensitive to reduced expression of post-synaptic genes
associated with SCZ and bipolar disorder.105 Network level
properties may be utilized to model the beta and gamma
oscillation perturbations observed in patients.106 Calcium- and
voltage-sensitive imaging either instead of or in conjunction with
microelectrode array recordings provide powerful options to
observe activity oscillations in neuronal networks. Many of
molecular phenotyping methods, such as transcriptomic and cell
morphology analyses can be combined with these electrophysio-
logical assays in high throughput to facilitate a multimodal
assessment of many patient-derived iPSC lines.
CHALLENGES FOR IPSC-BASED DISEASE MODELS
Modeling psychiatric disorders at the cellular level is not without
difﬁculties and there are many potential sources of error. First, to
faithfully model diseases it is important that variation detected
between the iPSC lines reﬂects the underlying genetic differences
associated with the disorder, and is not introduced by cell
reprogramming or downstream effects of cell culturing and
differentiation protocols. This is particularly crucial when cellular
differences between cases and controls are expected to be subtle.
Substantial experimental variation between iPSC lines can arise
from inconsistency in iPSC reprogramming protocols, parental
somatic cell type107 and persistent epigenetic modiﬁcations;108,109
interline variability due to genetic instability, mosaicism or
accumulation of mutations during cell line expansion;110 and
intra-line variability arising during prolonged cell culturing and
differences in growth conditions.107,111–113 However, methods for
reprogramming have steadily improved since Takahashi and
Yamanaka27 ﬁrst described iPSC, and recent studies show that
by following standardized protocols reprogramming and cell
culturing consistency can be achieved and intra-line variation
reduced.114–116 Evidence for the equivalence of human iPSC and
embryonic stem cells indicate that reprogramming can instate a
pluripotent state similar to that of the inner cell mass of an early
human embryo.117 Interestingly, the epigenetic erasure that
occurs during the reprogramming process appears to make gene
expression in iPSC more dependent on the genotype compared
with gene expression in the cells used for reprogramming, in
which interline variability is much larger.118 The maturity of
iPSC-derived neurons is a concern in studies of neuronal networks
since they initially appear to most closely resemble fetal brain
cells.66,98,119,120 Different methods have been developed to
promote the maturation of iPSC-derived neurons, that is, trans-
plantation into rodent brains may mature them into GABAergic
interneuron for up to 7 months.120 Aging of iPSC-derived
dopaminergic neurons by induction of progerin expression
revealed disease phenotypes such as pronounced dendrite
degeneration, progressive loss of tyrosine hydroxylase expression,
enlarged mitochondria and Lewy body-precursor inclusions.121
Second is the question of choosing the best patient and control
cell combinations. Early iPSC studies did not always fully consider
possible confounders, such as differences in genetic background,
unmatched age, sex, and ancestry between patients and control
individuals, as well as differences in passage number of the iPSC
lines.74 It has become clear that these factors need to be carefully
considered when selecting appropriate healthy control iPSC.75 For
many studies, samples derived from healthy family members of
the patient with similar genetic background but not diagnosed
with disease currently represent the most feasible control.77
An ideal control would be an isogenic iPSC line generated by
correcting the genetic lesion(s) of the patient-derived iPSC line. In
recent years, novel techniques for genome-editing have greatly
increased level of efﬁciency of gene targeting in vitro. Using
engineered endonucleases such as zinc ﬁnger nucleases, TALENs
or CRISPR/Cas9, it is now possible to genome edit iPSC with high
speciﬁcity.76 For monogenic diseases, isogenic gene-corrected
iPSC lines represent an ideal control population. However, for
complex disorders with multiple genetic loci contributing to the
disease, editing approaches face limitations. Although editing of
multiple loci is feasible,122 gene correction of a larger number of
disease-associated variants in a single iPSC line remains proble-
matic. In principle, a disease versus control scenario could also be
generated by active introduction of candidate mutations into
‘healthy’ iPSC via gene editing. However, at present this route too
appears only feasible for diseases with relatively small numbers of
highly penetrant mutations. Furthermore, it comes with the
signiﬁcant disadvantage that phenotypic alterations in such
in vitro-mutated iPSC cannot be correlated with the clinical history
of an individual patient.78
Currently, parallel studies on isogenic gene-corrected iPSC for
selected variants and cells derived from unaffected family
members will remain the most feasible controls for comparative
phenotypic analysis of patient-derived iPSC. These studies could
be supplemented by the reverse experiment of using genome
editing to introduce additional gene mutations into patient or
non-patient cell lines with a high polygenic risk score derived by
classic reprogramming to create artiﬁcial ‘hyperphenotypes’,
where the effects of different patient backgrounds can be studied
on highly penetrant disease-associated variants (Figure 2a).
However, such approaches still face several limitations such as
difﬁculties in engineering large chromosomal deletions. Further
challenges include the large number of single nucleotide
polymorphisms in linkage disequilibrium and limited information
to guide the choice of relevant variants (Table 3).
Finally, inter-individual variability of patients with similar
diagnosis and subtle differences in the clinical disease progression
will result in quantitative, and perhaps qualitative, differences
in cell phenotypes between iPSC lines derived from different
patients.110 It is therefore necessary to have the capacity to handle
large-sample sizes for modeling these complex disorders.
Comprehensive exploration of the steadily increasing number of
risk loci in iPSC-based models will only be possible using large
cohorts of patients and controls. To assess the combined impact
of genetic variants on a single background or to decipher the
single contribution of each variant, it will be necessary to explore
novel technical solutions that enable much higher throughput. To
that end, automated modules covering key reprogramming steps
such as transfection, media changes, splitting and colony picking
are already being implemented.123 It is foreseeable that auto-
mation will move towards large-system integrations enabling fully
automated production of iPSC on industrial production-line
platforms such as the StemCellFactory (www.stemcellfactory.de;
Figure 2b). While automated cell culture provides key advantages
with respect to standardization and parallelization, large-system
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Table 3. Potential and limitations of gene editing strategies at mono- and multigenic level
Modiﬁcation Potential Limitations Alternatives
Monogenic Genetic correction of patient backgrounds
provides ideal isogenic controls for in vitro
disease modeling (reduced experimental
‘noise’)
Strategy cannot be faithfully applied to
diseases based on large CNVs (for example,
chromosomal deletion syndromes).
(i) Inducible expression of candidate
transgene targeted to genomic ‘safe
harbor’ locus151 (ii) Engineering allelic
series into isogenic standard
background149
Multigenic Introduction of additional risk variants or
protective alleles into patient backgrounds
could provide mechanistic insight into
disease modulation and serve as a tool to
aggravate or mitigate in vitro phenotypes
Variant modeling studies are complicated
by (i) the large number of SNPs in linkage
disequilibrium and (ii) limited information
to guide the choice of relevant variants.
Automated high-throughput in vitro
analysis of patient cohorts stratiﬁed
according to risk and/or protective factors
(Figure 2).
Abbreviation: CNV, copy number varient; SNP, single nucleotide polymorphism.
Table 4. Advantages and challenges of automated cell culture systems for cell reprogramming and differentiation
Advantages Challenges
High degree of standardization Requires robust cell culture protocols amenable to robotic handling
High level of parallelization enabling handling of large
cohorts
Requires complex, self-scheduling software
Little hands-on time; 24/7 operation; remote, web-based
control
High cost; requires trained engineering staff and manual emergency plans for cases
of catastrophic machine failure
Can accommodate genetic modiﬁcation Special requirements for viral transduction systems (for example, Sendai virus)
Facilitates seamless bar code-based documentation of all
handling steps
Requires innovative fast imaging strategies and handling/storage of large data
volumes
Figure 2. Automated production and differentiation of iPSCs. (a) Conventional disease modeling or drug evaluation approaches mostly rely
on a small number of disease-speciﬁc, as well as control iPSC lines and largely ignore the impact of genetic variability on pathological
pathways or drug targets. Parallelization of reprogramming and subsequent differentiation would allow assessing phenotypic variation or to
validate candidate drugs on multiple genomic backgrounds, for example, stratiﬁed patient or control cohorts. (b) Fully integrated robotic
systems such as the StemCellFactory (www.stemcellfactory.de) are expected to allow high-throughput reprogramming and differentiation
under controlled and standardized conditions, and thus to minimize line-to-line heterogeneity induced by non-standardized manual handling
steps. Kindly provided by Andreas Elanzew, Simone Haupt (Life & Brain, Bonn, Germany) and the Fraunhofer Institute for Production
Technology (IPT). iPSC, induced pluripotent stem cell.
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integration units for robotic reprogramming come with their own
challenges (Table 4).
CONCLUSIONS AND FUTURE PERSPECTIVES
The proof-of-concept emerging from many recent studies that
have attempted to mimic aspects of psychiatric disorders in vitro
using patient-derived cells is very encouraging (Table 2). Increased
standardization, proper controls and new integrative robotic
systems will give solutions to many problems. However, there
remain a number of considerable challenges ahead.
Strategies moving forward need to take into account the
genetic characteristics of the patient population in which genetic
risk is largely polygenic, and a mixture of many common variants
of small effect, as well as few rare variants of large effect. In
contrast, a priori we would expect to ﬁnd the most robust
phenotypes in cells derived from patients carrying highly
genetically penetrant rare variants and cell models created using
genome editing of isogenic iPSC lines. It will be important to
connect the knowledge gained from single gene deﬁcits and that
gained from the accumulated effects of multiple subtle genetic
risk alleles.
Both the selection of patients carrying rare variants of large
effect and the selection of patients of extremely high polygenic
risk require large patient populations to optimize the selection.
When genetic risk in selected patients is not sufﬁciently causal,
any iPSC experiment will require the analysis of large numbers of
patient cell lines. An important step is to have robust protocols for
reprogramming and differentiation of large numbers of patient
samples. This will require standardization and rigorous quality
control to reduce technical variation to an acceptable minimum.
Given the high current reagent costs for stem cell research, the
unit price per patient cell assay needs to drop substantially before
this will be feasible. These processes need to integrate well with
global efforts in patient recruitment and accompanying clinical
phenotyping and genomic analysis.
Beyond the issues of variability and capacity lies the key
question of what is the relevant cellular phenotype or phenotypes.
We have discussed what is currently possible and under
development, and how these might relate to function and
physiology in the intact brain. However, these investigations have
only just begun, and are likely to require multiple lines of
converging evidence, carried out in numerous centers and with
validation against clinical and animal model studies, before
consensus cellular phenotypes can be established and accepted.
Finally, we need to consider what constitutes success in this
enterprise? Although iPSC-based systems provide a powerful
route to identifying molecular mechanisms underlying genetic
and other disease-related risks, in isolation they do not provide
information about brain physiology, higher order neuronal
circuitry and function or human psychology. Success might simply
be to create a reliable experimental link between genetics and
patient studies via cell physiology. Alternatively, we could set
more ambitious goals using iPSC to inform connectomic and
neuro-computational modeling, predict patient drug responses
and promote preclinical drug discovery. True success would be
achieved if analysis of iPSC-derived neuronal networks became a
standard assay for neurophysiologists, forming an integral
component of diagnostic and precision medicine for neuropsy-
chiatric disorders and facilitating the ﬁrst advent of new drugs
screened on patient iPSC reach the clinic.
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